Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda, a Swedish specialty pharmaceutical company, has announced that the FDA has approved Astepro - the new formulation of Astelin. Astepro is now approved for treatment of seasonal allergic rhinitis.
Subscribe to our email newsletter
Astepro nasal spray is said to be an improvement over the marketed Astelin nasal spray and is better tolerated by patients using the new spray.
Full launch of Astepro in the US will take place well before the next allergic rhinitis season, the company said.
Anders Lonner, CEO of Meda, said: “Our development team has done an excellent work answering the questions from the FDA and reaching approval in such a short time. This is an important milestone for Meda.”